Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluocinolone Acetonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | AR | P10275 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluocinolone Acetonide SCHEMBL15256220 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ALMNAPGRAR | |
| Fluocinolone Acetonide SCHEMBL4795 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ALMNAPGRAR | |
| Fluocinolone Acetonide SCHEMBL13046617 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ALMNAPGRAR | |
| Fluocinolone Acetonide SCHEMBL12323210 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ALMNAPGRAR | |
| Fluocinolone Acetonide SCHEMBL11911287 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ALMNAPGRAR | |
| Fluocinolone Acetonide SCHEMBL13799272 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ALMNAPGRAR | |
| Fluocinolone Acetonide SCHEMBL13695922 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ALMNAPGRAR | |
| Fluocinolone Acetonide SCHEMBL4116560 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ALMNAPGRAR | |
| Fluocinolone Acetonide SCHEMBL21153661 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ALMNAPGRAR | |
| Fluocinolone Acetonide SCHEMBL28266842 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ALMNAPGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234334-A1 | NITRIC OXIDE RELEASING STEROIDS | NICOX S.A. (FR) | 2010-09-16 | — | — | US | claimed |
| EP-1448202-A1 | COMBINATION OF A PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG | ALTANA Pharma AG (DE) | 2004-08-25 | — | — | EP | claimed |
| WO-2003039552-A1 | COMBINATION OF PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG | ALTANA PHARMA AG (DE) | 2003-05-15 | — | — | WO | claimed |
| US-20030092706-A1 | Combination | NYCOMED GMBH (DE) | 2003-05-15 | — | — | US | claimed |
| US-20100234334-A1 | NITRIC OXIDE RELEASING STEROIDS | NICOX S.A. (FR) | 2010-09-16 | — | — | US | disclosed |
| US-20070270441-A1 | Combination | ALTANA PHARMA AG (DE) | 2007-11-22 | — | — | US | disclosed |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | disclosed |
| EP-1448202-A1 | COMBINATION OF A PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG | ALTANA Pharma AG (DE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003039552-A1 | COMBINATION OF PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG | ALTANA PHARMA AG (DE) | 2003-05-15 | — | — | WO | disclosed |
| US-20030092706-A1 | Combination | NYCOMED GMBH (DE) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | NR3C1 104/4885HIF1A 1076/4885LMNA 4087/4885 |
| US-20100234334-A1 | NITRIC OXIDE RELEASING STEROIDS | NOS1, NR3C1, NOS2 | NR3C1 2/4885HIF1A 887/4885LMNA 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.